H-Type Hypertension Precision Medicine Trial
A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 3600 participants.
Also called NCT03472508
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 3,600 participants
- Sponsor
- Registry
-
NCT03472508
-
- Other papers using this trial's data
- Optimal folic acid dosage in lowering homocysteine: Precision Folic Acid Trial to lower homocysteine (PFAT-Hcy)
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Unknown status
Technical summary
Registry record NCT03472508. Randomized; double masking; primary purpose treatment. Start 2018-03-20 (actual); primary completion 2019-03-30 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- H-Type Hypertension Precision Medicine Trial
- Condition
- Hypertension
- Intervention (Drug)
- Folic Acid
- Intervention (Drug)
- Enalapril Maleate and Folic Acid Tablets (Yiye)
- Intervention (Drug)
- Enalapril
- Lead sponsor
- Shenzhen Ausa Pharmed Co.,Ltd
- Collaborator
- Second Affiliated Hospital of Nanchang University
- Collaborator
- Shenzhen Evergreen Medical Institute
- Collaborator
- Nanfang Hospital, Southern Medical University
- Collaborator
- Peking University First Hospital
- Collaborator
- The First People's Hospital of Lianyungang
- Collaborator
- People's Hospital of Rongcheng
- Collaborator
- Anhui Medical University
Record details
- Record id
cardio:ct-nct03472508- Content hash
32ad5b9de01e99e0cd8abfc3d73df5f66d5c3643737ed5970e7fb6d477230c6c